Alterity Therapeutics (ATHE) Return on Capital Employed (2019)

Alterity Therapeutics (ATHE) recorded quarterly Return on Capital Employed of 136.03% in Q4 2019.

Alterity Therapeutics (ATHE) Return on Capital Employed (2019) Analysis & Trends

Alterity Therapeutics' Return on Capital Employed history runs 1 years deep, the most recent figure standing at 136.03% for Q4 2019.

In Q4 2019, Return on Capital Employed changed N/A year-over-year to 136.03%; the TTM figure through Dec 2019 stood at 136.03% (changed N/A YoY), while the FY2023 annual figure was 61.44%, down 2262.0% from the prior year.
Return on Capital Employed was 136.03% for Q4 2019 at Alterity Therapeutics.
In the past five years, Return on Capital Employed ranged from a high of 136.03% in Q4 2019 to a low of 136.03% in Q4 2019.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	450.31%
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	51.73%
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-107.40%
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	21.10%
9	Abivax	91.96 Bn	91.96 Bn	-	-50.43%
10	Regeneron Pharmaceuticals	63.43 Bn	54.67 Bn	3.31 Bn	10.19%

Historic Data

Download Data

Date	Value
Dec 31, 2019	-136.03%